RIGOL

RIGOL Technologies Co., Ltd.
普源精電科技股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 00537)

ANNOUNCEMENT ON THE CHANGE OF REGISTERED CAPITAL AND AMENDMENTS TO THE ARTICLES OF ASSOCIATION

This announcement is made by Rigol Technologies Co., Ltd. (the "**Company**") pursuant to Rule 13.51(1) of the Rules Governing the Listing of Securities (the "**Hong Kong Listing Rules**") on The Stock Exchange of Hong Kong Limited (the "**Stock Exchange**").

On 25 August 2026, the board of directors (the "**Board**") of the Company considered and approved, among other matters, a resolution regarding the proposed amendments to the Company's Articles of Association (the "**Articles of Association**") (the "**Proposed Amendments**").

In light of the completion of the Company's H-share (the "**H Shares**") issuance and listing on the Stock Exchange, the Company's total share capital and registered capital have changed as follows: Upon filing with the China Securities Regulatory Commission and approval by the Stock Exchange, 24,802,200 H Shares issued by the Company were listed and commenced trading on the Main Board of the Stock Exchange on 9 July 2026. The Company's total share capital changed from 193,874,417 shares to 218,676,617 shares, and its registered capital changed from RMB193,874,417 to RMB218,676,617.

Based on the aforementioned changes in the Company's registered capital and share capital, as well as the listing and trading of the H Shares issued by the Company on the Main Board of the Stock Exchange, the Company proposes to amend the relevant provisions of the Articles of Association. A comparison table showing the provisions before and after the amendments is set out below:

Provision	**Before amendment**	**After amendment**
Article 3	Upon review by the Shanghai Stock Exchange and registration with the China Securities Regulatory Commission (the "CSRC") on March 1, 2022, the Company initially issued 30,327,389 RMB-denominated ordinary shares to the public, which were listed on the STAR Market of the Shanghai Stock Exchange on April 8, 2022. Upon the filing with the CSRC on 25 February 2026 and approval by the Hong Kong Stock Exchange (the "HKEX") on [•] 2026, the Company conducted the initial public offering of [•] overseas listed ordinary shares (the "H Shares") with an over-allotment of [•]H shares. The aforementioned H shares were listed on the HKEX on [•].	Upon review by the Shanghai Stock Exchange and registration with the China Securities Regulatory Commission (the "CSRC") on March 1, 2022, the Company initially issued 30,327,389 RMB-denominated ordinary shares to the public, which were listed on the STAR Market of the Shanghai Stock Exchange on April 8, 2022. Upon the filing with the CSRC on 25 February 2026 and approval by the Hong Kong Stock Exchange (the "HKEX") on 8 July 2026, the Company conducted the initial public offering of 24,802,200 overseas listed ordinary shares (the "H Shares"). The aforementioned H shares were listed on the HKEX on 9 July 2026.
Article 6	The registered share capital of the Company is RMB[•].	The registered share capital of the Company is RMB218,676,617.

Provision	Before amendment	After amendment
Article 20	Upon completion of the initial public offering of H shares, assuming the over-allotment option is not exercised, the total number of shares of the Company is [•], which are all ordinary shares and no other classes of shares. Among these, 193,874,417 are A ordinary shares, representing [•]% of the Company's total share capital, and [•] are H ordinary shares, representing [•]% of the Company's total share capital.	Upon completion of the initial public offering of H shares, the total number of shares of the Company is 218,676,617, which are all ordinary shares. Among these, 193,874,417 are A ordinary shares, and 24,802,200 are H ordinary shares.
Article 211	The Articles of Association have been deliberated and approved by the shareholders' general meeting and the overseas listed shares (H shares) issued by the Company will take effect and come into force on the date of listing on the Hong Kong Stock Exchange. After the implementation of the Articles of Association, the original Articles of Association will automatically become invalid. If there is any conflict between these Articles of Association and current laws and regulations, the current laws and regulations shall prevail. In addition, this article of association shall be filed with the company registration authority.	The Articles of Association shall take effect and come into force from the date of deliberation and approval by the shareholders' general meeting.

Except for the aforementioned provisions, the other provisions of the Articles of Association shall remain unchanged. The proposed amendments to the Articles of Association are subject to deliberation and approval by the Company's forthcoming extraordinary general meeting (the "**EGM**"). The Board will seek authorization from the EGM to authorize the Company's management or its authorized representatives to handle the filing of the Articles of Association with the relevant registration authorities and to complete procedures related to changes in registered capital and other matters.

The validity period of such authorization shall be from the date of deliberation and approval by the EGM until the date on which the relevant procedures of change/filing of industry and commerce are completed.

GENERAL

The Company will convene the EGM in due course and proposes that the Company's shareholders (the "**Shareholders**") consider, and if thought fit, approve the resolution regarding, among other matters, the Proposed Amendments. The notice of the EGM and a circular containing, among other things, details of the Proposed Amendments will be provided to the Shareholders in due course.

By order of the Board
RIGOL Technologies Co., Ltd.
普源精電科技股份有限公司
Dr. Wang Yue
Chairman and Executive Director

Hong Kong, August 25, 2026

As of the date of this announcement, the executive Directors are Dr. Wang Yue, Mr. Wang Ning, Dr. Sun Ningxiao and Mr. Cheng Jianchuan, and the independent non-executive Directors are Dr. Qin Ce, Dr. Liu Liansheng and Ms. Xu Xu.